Pfizer goes local with Russian joint venture - Doing Business With Russia

12 September 2016

Kira Egorova / Doing Business With Russia

The American pharmaceutical corporation is building a new facility south of Moscow to capitalize on support from government initiatives, which is also indicative of its commitment to the local market. 

In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.

By constructing a production facility in Russia, Pfizer is eligible to take advantage of Pharma 2020, a large-scale Russian government program offering subsidies to local manufacturers that produce medicines from the essential drugs list (EDL). All state hospitals and clinics are required to look to the EDL first for medicines for their patients. In addition to supporting local producers, the state program aims to increase the share of Russian drugs to 50 percent of the domestic market by 2020. During the first year that Pharma 2020 was in effect, the share of locally produced drugs in the domestic market doubled in value terms from 13 percent to 26 percent, according to the DSM Group marketing agency.

In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.

By constructing a production facility in Russia, Pfizer is eligible to take advantage of Pharma 2020, a large-scale Russian government program offering subsidies to local manufacturers that produce medicines from the essential drugs list (EDL). All state hospitals and clinics are required to look to the EDL first for medicines for their patients. In addition to supporting local producers, the state program aims to increase the share of Russian drugs to 50 percent of the domestic market by 2020. During the first year that Pharma 2020 was in effect, the share of locally produced drugs in the domestic market doubled in value terms from 13 percent to 26 percent, according to the DSM Group marketing agency.

An agreement of cooperation was signed in Moscow on July 12 by Pfizer and NovaMedica representatives, including Anatoly Chubais, an influential member of the presidential administration in the early 1990s and now head of the state-owned company Rusnano. Press Photo

HIGH-TECH PRODUCTION

According to Pfizer’s press service, the portfolio of high-tech medicinal products planned for the new plant in the Kaluga Region includes essential drugs for the treatment of severe bacterial and fungal infections, inflammatory diseases, cancer and for use in anesthesiology — more than 30 INNs (international nonproprietary names for active pharmaceutical ingredients).

"Most of these INNs that are to be produced in Kaluga are on the EDL and several are also in the federal reimbursement programs Population Drug Coverage [ONLS] and one called 7 Nosologies [7N]," said a representative of Pfizer’s press service. "Based on our estimates, these medicines are in high demand on the Russian market. Following the priorities denoted by the Ministry of Health and the Ministry of Industry and Trade of the Russian Federation, Pfizer strives to provide a maximum amount of Russian patients with access to Pfizer medicines.”

Pfizer will provide NovaMedica with technology licenses for the production of more than 30 drugs. The construction of the plant will begin this year and its launch is scheduled for 2020.

"We do not disclose the size of Pfizer's investment, but we can say that this is a significant amount," said Alexander Kuzin, the managing director of NovaMedica. "The remaining funds will be invested in the construction of the plant by NovaMedica's shareholders."

In an interview earlier this year with the Russian business daily Vedomosti, Leonid Melamed, a member of NovaMedica's board of directors, estimated the cost of the project at $60-100 million.

Kuzin says that the joint Pfizer-NovaMedica project is taking a different approach to production than is typical in Russia.

"In Russia, new pharmaceutical facilities are often built without focusing on specific drugs," Kuzin said. "We sought to form the portfolio first and then build the plant, taking into account the specifics of the portfolio of the products that will be produced there."

Kuzin said he considers this to be a cost-effective method of development, providing a strong foundation for the commercial success of the project.

The Pfizer-NovaMedica project also has a different concept for localization than past joint ventures. International pharmaceutical companies used to practice one of two localization strategies in Russia: they either built their own production facilities or bought an existing one. Instances of this latter example include U.S. company Abbott’s purchase of Russia's Veropharm in 2014, France's Sanofi acquisition of a local plant in 2009 and Germany's Stada ownership of the Russian plant Nizhpharm since 2005.

MARKET DYNAMICS
 

Over the past six years, the Russian pharmaceutical market has become very popular among investors. It has also shown resilience to the country’s crisis, the devaluation of the ruble and the reduced purchasing power of Russians.

"Indeed, since 2010 investors have invested more than $2 billion in the Russian pharmaceutical industry and, perhaps this figure will double by the end of the next decade," said Vasily Ignatiev, the CEO of the R-Pharm group of companies.

According to the Federal State Statistics Service Rosstat, the volume of production of medicines increased by nearly 27 percent in 2015 compared to 2014, totaling 231 billion rubles ($3.6 billion).

"There are positive dynamics in national pharma manufacturing," Ignatiev said.

Growth in the sector along with the ruble devaluation has encouraged international players to invest in large-scale projects in the region.

"In Russia, several key production centers have appeared," said Ignatiev. "These are pharmaceutical clusters in the Yaroslavl and Kaluga regions – not far from Moscow. The historically developed industrial base in the Moscow Region continues to evolve."

EXPORT POTENTIAL
 

Given the growth in the domestic market, the Russian government, led by Prime Minister Dmitry Medvedev, has become interested in the possibility of exporting Russian medicines. At the end of July, Medvedev instructed the Ministry of Trade and Industry to study the issue of funding clinical trials abroad on a returnable basis. A report is expected in September.

Exports are already the fastest growing segment of the Russian pharmaceutical market. In 2015, total exports amounted to $340 million, which is 45 percent more than in 2014 according to data from the analytical firm RNC Pharma.

NovaMedica and Pfizer did not confirm the possibility of exporting pharmaceuticals from their new plant. However, NovaMedica stressed that the plant will be built in compliance with international GMP (Good Manufacturing Practice) and FDA (U.S. Food and Drug Administration) standards, leaving the option open.

"The plant will have the opportunity to expand as new products appear in NovaMedica's portfolio for localization," Kuzin said.

Victor Dmitriev, the CEO of the Association of Russian Pharmaceutical Manufacturers, acknowledged that the possibility for export exists.

"It would be logical for Pfizer and NovaMedica to offer part of the Kaluga plant's products for export," he said, noting that the international players working in Russia have long been looking to export their products. Sanofi has already announced its plans to export insulin to Europe, while Germany's Stada is already sending a number of drugs it produces in Russia to Germany.

Another U.S. company – Abbott, which produces high-quality affordable medicines for cancer and chronic diseases at its Veropharm plant in Russia – is also considering the possibility of export.

"Our program aims at transforming Veropharm into a world-class manufacturer that could at some point export to other countries" besides former Soviet ones, said Irina Gushchina, the public affairs director of Abbott Russia. “Veropharm’s medicines have a great potential for growth due to the growing prevalence of oncology and chronic diseases both in Russia and globally.”

The company already exports medicines within the post-Soviet bloc.

Today, Russia exports about 11 percent of its pharmaceutical medicines. A total of 100 countries import drugs and dietary supplements from Russia, although more than 70 percent of Russian exports go to former Soviet republics, such as Uzbekistan and Lithuania, according to data from RNC Pharma. A smaller share goes to China, Angola, Iraq, Cuba, Congo, Syria and Vietnam. Of the Russian producers, only Evalar is working in the U.S. market. It currently supplies food additives.

"It is highly probable that Pfizer and NovaMedica's plant in Kaluga will start exporting" to former Soviet countries, said Nikolai Demidov, CEO of the analytical company IMS Health. "[But] it is unlikely that exports from this plant will amount to more than 5-6 percent of sales in the first years of work."

Deliveries to Europe and other foreign countries outside the former Soviet Union are less likely. According to Demidov, despite the devaluation of the ruble, which significantly reduced the cost of production of medicines in Russia, transportation and investments in upgrading production facilities to meet international standards significantly increase the final cost of Russian-made drugs.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more